TheraPten Biosciences

TheraPten Biosciences is a private Canadian preclinical oncology biotechnology company developing therapies based on restoration of the PTEN tumor suppressor. The company is focused on delivering cell-permeable PTEN, including lipid nanoparticle-formulated candidates intended for intravenous administration to kill cancer cells that have lost PTEN function. Its lead disclosed program appears to be PR61, and public descriptions also reference a broader PTEN fusion and manufacturing platform. TheraPten has collaborated with the Canadian National Research Council on preclinical studies. Overall, the company is positioned as an early-stage oncology platform biotech centered on PTEN replacement biology.